Bristol-Myers Squibb Q1 2026 Earnings Analysis
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Bristol-Myers Squibb Q1 2026 Earnings Analysis
-
ナレーター：
-
著者：
概要
**ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and joining me as always is Jordan. Today we're diving into Bristol-Myers Squibb's first quarter 2026 results, and there's quite a lot to unpack here.
**JORDAN**: Absolutely, Alex. But before we get started, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**ALEX**: Thanks for that, Jordan. Now, let's talk Bristol-Myers Squibb - ticker BMY. This pharmaceutical giant just reported Q1 results, and honestly, they seem to be firing on multiple cylinders right now.
**JORDAN**: The numbers tell a solid story, Alex. Total revenue came in at $11.5 billion, up 1% year-over-year. But here's what's really interesting - their growth portfolio, which includes their newer, more innovative drugs, grew 9% to $6.2 billion. That's nearly half their total revenue now coming from these growth assets.
**ALEX**: That's a massive shift for a company that's been dealing with patent cliffs on older drugs. What stood out to you in terms of specific products driving this growth?
**JORDAN**: Several winners here. Reblozyl grew 15%, Breyanzi - their CAR-T cell therapy - jumped 53%, and Camzyos nearly doubled to $314 million. But the elephant in the room is still Eliquis, their blood thinner, which brought in $4.1 billion and grew 13% despite facing generic competition eventually.
**ALEX**: Let's talk about what CEO Chris Boerner emphasized during the call. He really hammered home three strategic priorities: focusing R&D on life-threatening diseases, executing on their growth portfolio, and maintaining disciplined capital allocation. But Jordan, what caught my attention was all the talk about late 2026 being a make-or-break period for several key programs.
**JORDAN**: Yes, this is crucial, Alex. They have what Boerner called an "increasing cadence of pivotal readouts" coming in late 2026. We're talking about Milvexian for atrial fibrillation and stroke prevention, Cobenfy for Alzheimer's psychosis, and some important cancer drug data. These aren't just incremental updates - these could define the company's growth trajectory for years.
**ALEX**: Let's break down a couple of these. Milvexian is their Factor XI inhibitor, essentially trying to create a blood thinner with less bleeding risk than current options. How big could this be?
**JORDAN**: Potentially massive, Alex. They're testing it against Eliquis - their own blockbuster drug - trying to show it's just as effective but causes less bleeding. Think about it: if you can reduce the main side effect that keeps doctors from prescribing blood thinners, you could expand the treatable patient population significantly. Adam Lenkowsky, their Chief Commercialization Officer, called it having "true blockbuster potential."
**ALEX**: And then there's Cobenfy, which they're testing in Alzheimer's psychosis. This seems like a completely different approach to treating psychiatric symptoms in dementia patients.
**JORDAN**: Right, and this addresses a huge unmet need. Current antipsychotics used in elderly dementia patients carry black box warnings and cause serious side effects like movement disorders and cognitive impairment. Cobenfy works on a completely different mechanism - muscarinic receptors instead of dopamine. If it works, it could be the first approved treatment specifically for Alzheimer's psychosis.
**ALEX**: Now, during the Q&A, there were some really interesting exchanges. One analyst asked about their confidence levels in these trials, and Chief Medical Officer Cristian Massacesi gave pretty detailed responses about trial design and patient selection.
**JORDAN**: What struck me was how specific they we
This episode includes AI-generated content.
まだレビューはありません